Abstract: Novel N4-substituted decitabine analogs are disclosed that exhibit promising in vitro and in vivo therapeutic activity. These novel compounds were shown to be resistant to deamination via cytidine deaminase (CDA) metabolism and provide a unique pharmacokinetic profile versus decitabine, while retaining the ability to induce DNA demethylation in target cells. These novel compounds can be used for treating hematological cancers, as well for new therapeutic interventions, including bacterial or viral pneumonia, acute respiratory distress syndrome, pulmonary fibrosis, transplantation and checkpoint inhibitor-induced adverse events, including pneumonitis.

Abstract: The present invention provides methods and compositions for treatment of acute inflammatory diseases or disorders and/or for treatment of lung injury. Certain exemplary methods involve administering an IL-4 polypeptide or fragment thereof possessing cytokine activity or an IL-4 agonist systemically to a subject having an inflammatory disease or disorder and/or a lung injury. Other exemplary methods involve administering an inhibitor of DNA methylation systemically to a subject and/or administering an inhibitor of DNA methylation to a cell population comprising T cells (e.g., Treg cells) for introduction/re-introduction to a subject having an inflammatory disease or disorder and/or a lung injury. Compositions and cells for use in such methods are also provided.

Abstract: The present invention provides methods and compositions for treatment of acute inflammatory diseases or disorders and/or for treatment of lung injury. Certain exemplary methods involve administering an IL-4 polypeptide or fragment thereof possessing cytokine activity or an IL-4 agonist systemically to a subject having an inflammatory disease or disorder and/or a lung injury. Other exemplary methods involve administering an inhibitor of DNA methylation systemically to a subject and/or administering an inhibitor of DNA methylation to a cell population comprising T cells (e.g., Treg cells) for introduction/re-introduction to a subject having an inflammatory disease or disorder and/or a lung injury. Compositions and cells for use in such methods are also provided.

Abstract: The present invention provides methods and compositions for treatment of acute inflammatory diseases or disorders and/or for treatment of lung injury. Certain exemplary methods involve administering an IL-4 polypeptide or fragment thereof possessing cytokine activity or an IL-4 agonist systemically to a subject having an inflammatory disease or disorder and/or a lung injury. Other exemplary methods involve administering an inhibitor of DNA methylation systemically to a subject and/or administering an inhibitor of DNA methylation to a cell population comprising T cells (e.g., Treg cells) for introduction/re-introduction to a subject having an inflammatory disease or disorder and/or a lung injury. Compositions and cells for use in such methods are also provided.